Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells

Journal of Gene Medicine

Volumn 11, Issue 2, 2009, Pages 103-111

  Kamata, Masakazu ^a   Susanto, Melisa T ^a   Chen, Irvin S Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyloidosis; Gene therapy; Lentiviral vector; Neuropathy; Transsuppressor; Transthyretin (TTR)

Indexed keywords

ACETYLSALICYLIC ACID; LENTIVIRUS VECTOR; MUTANT PROTEIN; PREALBUMIN; RETINOL BINDING PROTEIN;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STABILITY; VIRAL GENE THERAPY; WESTERN BLOTTING; ANIMAL; GENE VECTOR; GENETICS; HUMAN; LENTIVIRINAE; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MUTATION; TUMOR CELL LINE;

MAMMALIA; MUS;

AMYLOIDOSIS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENETIC VECTORS; HUMANS; LENTIVIRUS; LIVER NEOPLASMS; MICE; MUTATION; PREALBUMIN;

EID: 62249114267     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1276     Document Type: Article

References (39)

1. Pepys MB. Amyloidosis. Annu Rev Med 2006; 57: 223-241.
2. Buxbaum JN. The systemic amyloidoses. Curr Opin Rheumatol 2004; 16: 67-75.
3. Obici L, Perfetti V, Palladini G, et al. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005; 1753: 11-22.
4. Costa PP, Figueira AS, Bravo FR. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci USA 1978; 75: 4499-4503.
5. Saraiva MJ, Birken S, Costa PP, et al. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 1984; 74: 104-119.
6. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005; 62: 1057-1062.
7. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007; 36: 411-423.
8. Costa R, Goncalves A, Saraiva MJ, et al. Transthyretin binding to A-Beta peptide - impact on A-Beta fibrillogenesis and toxicity. FEBS Lett 2008; 582: 936-942.
9. Saraiva MJ. Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum Mutat 2001; 17: 493-503.
10. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952; 75: 408-427.
11. Kanda Y, Goodman DS, Canfield RE, et al. The amino acid sequence of human plasma prealbumin. J Biol Chem 1974; 249: 6796-6805.
12. Bellovino D, Morimoto T, Pisaniello A, et al. In vitro and in vivo studies on transthyretin oligomerization. Exp Cell Res 1998; 243: 101-112.
13. Sato T, Susuki S, Suico MA, et al. Endoplasmic reticulum quality control regulates the fate of transthyretin variants in the cell. EMBO J 2007; 26: 2501-2512.
14. Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell 2005; 121: 73-85.
15. Monaco HL, Rizzi M, Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 1995; 268: 1039-1041.
16. Hamilton JA, Benson MD. Transthyretin: a review from a structural perspective. Cell Mol Life Sci 2001; 58: 1491-1521.
17. Sebastiao MP, Saraiva MJ, Damas AM. The crystal structure of amyloidogenic Leu55 - > Pro transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils. J Biol Chem 1998; 273: 24715-24722.
18. Quintas A, Vaz DC, Cardoso I, et al. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 2001; 276: 27207-27213.
19. Hammarström P, Jiang X, Hurshman AR, et al. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 2002; 99(Suppl 4): 16427-16432.
20. Reixach N, Deechongkit S, Jiang X, et al. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 2004; 101: 2817-2822.
21. Alves IL, Divino CM, Schussler GC, et al. Thyroxine binding in a TTR Met 119 kindred. J Clin Endocrinol Metab 1993; 77: 484-488.
22. Alves IL, Altland K, Almeida MR, et al. Screening and biochemical characterization of transthyretin variants in the Portuguese population. Hum Mutat 1997; 9: 226-233.
23. Coelho T, Chorao R, Sousa A, et al. Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromuscul Disord 1996; 27: S20.
24. Harrison HH, Gordon ED, Nichols WC, et al. Biochemical and clinical characterization of prealbuminCHICAGO: an apparently benign variant of serum prealbumin (transthyretin) discovered with high-resolution two-dimensional electrophoresis. Am J Med Genet 1991; 39: 442-452.
25. Longo Alves I, Hays MT, Saraiva MJ. Comparative stability and clearance of [Met30]transthyretin and [Met119]transthyretin. Eur J Biochem 1997; 249: 662-668.
26. Almeida MR, Alves IL, Terazaki H, et al. Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119M. Biochem Biophys Res Commun 2000; 270: 1024-1028.
27. Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science 2001; 293: 2459-2462.
28. Kung SK, Bonifacino A, Metzger ME, et al. Lentiviral vector-transduced dendritic cells induce specific T cell response in a nonhuman primate model. Hum Gene Ther 2005; 16: 527-532.
29. Kang Y, Stein CS, Heth JA, et al. In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River virus glycoproteins. J Virol 2002; 76: 9378-9388.
30. Yuan H, Kamata M, Xie YM, et al. Increased levels of Wee-1 kinase in G2 are necessary for Vpr- and gamma irradiation-induced G2 arrest. J Virol 2004; 78: 8183-8190.
31. Rostom AA, Sunde M, Richardson SJ, et al. Dissection of multiprotein complexes using mass spectrometry: subunit interactions in transthyretin and retinol-binding protein complexes. Proteins 1998; (Suppl 2): 3-11.
32. Bellovino D, Morimoto T, Tosetti F, et al. Retinol binding protein and transthyretin are secreted as a complex formed in the endoplasmic reticulum in HepG2 human hepatocarcinoma cells. Exp Cell Res 1996; 222: 77-83.
33. Nakai H, Fuess S, Storm TA, et al. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 2005; 79: 214-224.
34. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
35. Klabunde T, Petrassi HM, Oza VB, et al. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol 2000; 7: 312-321.
36. Almeida MR, Gales L, Damas AM, et al. Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr Drug Targets CNS Neurol Disord 2005; 4: 587-596.
37. Sacchettini JC, Kelly JW. Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov 2002; 1: 267-275.
38. Nakamura M, Ando Y, Nagahara S, et al. Targeted conversion of the transthyretin gene in vitro and in vivo. Gene Ther 2004; 11: 838-846.
39. Andersen MS, Sorensen CB, Bolund L, et al. Mechanisms underlying targeted gene correction using chimeric RNA/DNA and single-stranded DNA oligonucleotides. J Mol Med 2002; 80: 770-781.